Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.

Dr. Alexander notes his general tendency to initiate stabilizers for most newly diagnosed patients given the established standard of care, longer-term data, and favorable tolerability. However, he identifies patients with mixed phenotype disease, meaning both neuropathy and cardiomyopathy, as candidates where vutrisiran may be preferred, as silencers are the only class studied in neuropathy to date. Regarding combination therapy, he reserves this approach primarily for patients with more advanced or progressive disease, while acknowledging that early-stage patients on monotherapy tend to do very well and may not require it.

From a payer perspective, Dr. Alexander suggests that when therapies are clinically comparable, cost becomes a more relevant differentiating factor, and that real-world evidence generation will be critical for informing future coverage decisions. Dr. Haumschild adds that Emory's approach involves a multidisciplinary disease state working group, integrating input from amyloidosis subspecialists and community cardiologists alongside specialty pharmacy data and cost-effectiveness analysis to establish consistent, patient-appropriate treatment frameworks.

The next episode in this series, ‘Applying Value-Based Frameworks in ATTR-CM Management,’ features the panelists advancing their conversation on ATTR-CM and focusing on how value-based frameworks, real-world evidence generation, and cross-institutional collaboration can help payers and providers better evaluate the clinical and economic impact of disease-modifying therapies in the absence of head-to-head data.